BACKGROUND: We report on acute toxicities as well as the early cosmetic outcome of patients receiving intraoperative radiotherapy (IORT) followed by whole-breast radiotherapy (WBRT) compared to patients treated with standard WBRT alone. PATIENTS AND METHODS: From 2/2002 until 2/2005, 84 breast cancer patients were treated with IORT during breast-conserving surgery (BCS) as a boost (20 Gy/50 kV X-rays) followed by WBRT. After wound healing, all IORT patients were treated with WBRT at a total dose of 46 Gy. For the purpose of comparison, 53 patients treated consecutively between 1/2003 and 12/2004 in our institution with BCS followed by WBRT at a total dose of 50-66 Gy, were analyzed. All patients had a defined followup schedule. Toxicities were prospectively documented using the CTC/EORTC Score. Cosmesis was evaluated after 6 months using a 1-4 score. RESULTS: Treatment was well tolerated with no grade 3/4 acute toxicity. Rare adverse effects following IORT included wound healing problems (2%), erythema grade I-II (3%), palpable seroma (6%) and mastitis (2-4%). The number of patients with induration of the tumor bed was comparably low. CONCLUSION: IORT with the IntrabeamTM system applied as a boost during BCS, followed by 46 Gy WBRT, exerts similar acute toxicity as standard WBRT. Further follow-up is needed to assess long-term toxicity and efficacy.
BACKGROUND: We report on acute toxicities as well as the early cosmetic outcome of patients receiving intraoperative radiotherapy (IORT) followed by whole-breast radiotherapy (WBRT) compared to patients treated with standard WBRT alone. PATIENTS AND METHODS: From 2/2002 until 2/2005, 84 breast cancerpatients were treated with IORT during breast-conserving surgery (BCS) as a boost (20 Gy/50 kV X-rays) followed by WBRT. After wound healing, all IORT patients were treated with WBRT at a total dose of 46 Gy. For the purpose of comparison, 53 patients treated consecutively between 1/2003 and 12/2004 in our institution with BCS followed by WBRT at a total dose of 50-66 Gy, were analyzed. All patients had a defined followup schedule. Toxicities were prospectively documented using the CTC/EORTC Score. Cosmesis was evaluated after 6 months using a 1-4 score. RESULTS: Treatment was well tolerated with no grade 3/4 acute toxicity. Rare adverse effects following IORT included wound healing problems (2%), erythema grade I-II (3%), palpable seroma (6%) and mastitis (2-4%). The number of patients with induration of the tumor bed was comparably low. CONCLUSION: IORT with the IntrabeamTM system applied as a boost during BCS, followed by 46 Gy WBRT, exerts similar acute toxicity as standard WBRT. Further follow-up is needed to assess long-term toxicity and efficacy.
Authors: K Wasser; C Schoeber; U Kraus-Tiefenbacher; L Bauer; J Brade; J Teubner; F Wenz; W Neff Journal: Eur Radiol Date: 2007-01-20 Impact factor: 5.315
Authors: Julia Kaiser; Roland Reitsamer; Peter Kopp; Christoph Gaisberger; Michael Kopp; Thorsten Fischer; Franz Zehentmayr; Felix Sedlmayer; Gerd Fastner Journal: Breast Care (Basel) Date: 2018-05-30 Impact factor: 2.860
Authors: J Burgos-Burgos; V Vega; D Macias-Verde; V Gómez; M Travieso-Aja; J Travieso; E Vicente; C Santana; J Ospina; P C Lara Journal: Clin Transl Oncol Date: 2020-05-22 Impact factor: 3.405
Authors: Felix Sedlmayer; Roland Reitsamer; Christoph Fussl; Ingrid Ziegler; Franz Zehentmayr; Heinz Deutschmann; Peter Kopp; Gerd Fastner Journal: Int J Breast Cancer Date: 2014-09-02
Authors: Rick G Pleijhuis; Maurits Graafland; Jakob de Vries; Joost Bart; Johannes S de Jong; Gooitzen M van Dam Journal: Ann Surg Oncol Date: 2009-07-17 Impact factor: 5.344
Authors: Benjamin Tuschy; Sebastian Berlit; Simone Romero; Elena Sperk; Frederik Wenz; Sven Kehl; Marc Sütterlin Journal: Radiat Oncol Date: 2013-04-22 Impact factor: 3.481